{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:25:05Z","timestamp":1761848705170,"version":"build-2065373602"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10147-025-02879-y","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T03:43:42Z","timestamp":1757907822000},"page":"2159-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Noriomi","family":"Matsumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Mandai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2879_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) List of approved drugs. https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0010.html. Accessed 29 Aug 2025 in Japanese"},{"key":"2879_CR2","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 T, Overman MJ, Yoshino T et al (2024) Nivolumab plus ipilimumab in microsatellite-instability\u2013high metastatic colorectal cancer. N Engl J Med 391:2014\u20132026. https:\/\/doi.org\/10.1056\/NEJMoa2402141","journal-title":"N Engl J Med"},{"key":"2879_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ et al (2025) Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet 405:383\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(24)02848-4","journal-title":"Lancet"},{"key":"2879_CR4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 391:2110\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"2879_CR5","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1200\/JCO-25-00690","volume":"43","author":"M Wang","year":"2025","unstructured":"Wang M, Salek D, Belada D et al (2025) Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol 43:2276\u20132284. https:\/\/doi.org\/10.1200\/JCO-25-00690","journal-title":"J Clin Oncol"},{"key":"2879_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL et al (2018) Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391:659\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(17)33108-2","journal-title":"Lancet"},{"key":"2879_CR7","unstructured":"AstraZeneca (2025) Package insert for acalabrutinib. https:\/\/www.kegg.jp\/medicus-bin\/japic_med?japic_code=00071596. Accessed 29 Aug 2025 in Japanese"},{"key":"2879_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency (2025) Revisions of PRECAUTIONS (FY2025). https:\/\/www.pmda.go.jp\/english\/safety\/info-services\/drugs\/revision-of-precautions\/0013.html. Accessed 29 Aug 2025"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02879-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02879-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02879-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:06:52Z","timestamp":1761847612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02879-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2879"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02879-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"15 September 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}